Drugs and patents in ATC class C04 - PERIPHERAL VASODILATORS

Last updated: July 21, 2026

Executive summary

ATC Class C04 (peripheral vasodilators) is a mixed category dominated by small-molecule vasodilators, with patent risk concentrated in branded “legacy” molecules that still have active exclusivities via line extensions (reformulations, fixed-dose combinations, and method-of-use).
Patent estate intensity varies by sub-class: prostacyclin-pathway agents and nitric-oxide/guanylate-based drugs tend to have fewer but higher-impact patents; older agents with long market histories often have expiration-compliance windows driven by formulation and device-adjacent claims.
Generic entry is typically most feasible after API patent expiry plus any patent thickets tied to specific formulations, dosing regimens, or combination products; Paragraph IV challenges are more common when Orange Book listings show a clean path around granted claims.
The practical battleground is usually not “entire class” exclusivity, but specific brand-to-generic mappings for each active ingredient and each marketed dosage form.

What drugs are in ATC Class C04 peripheral vasodilators, and which are patent-relevant in major markets?

Featured snippet answer: C04 peripheral vasodilators includes multiple therapeutic agents across different pharmacology buckets; patent relevance is highest for branded products with Orange Book listings in the US and marketed reformulations in the EU/UK.

Key sub-buckets within C04 that drive IP and regulatory scrutiny

Common commercial and investigational focal points in C04 include:

Prostacyclin pathway / prostaglandin analog-related vasodilators (often used in pulmonary hypertension and sometimes cross-leveraged in peripheral circulation indications, depending on labeling)
Nitric oxide (NO) and guanylate cyclase pathway drugs (including sGC stimulators/modulators when marketed for peripheral vascular indications)
PDE5 inhibitors and related cyclic nucleotide modulators (some marketed cross-indications; patent estates frequently center on use and formulation)
Calcium channel blocker or direct vasodilator legacy actives used for peripheral circulation symptoms in some geographies
Other peripheral vasodilator small molecules packaged as single-ingredient or combinations

Why “class-level” patent analysis breaks

ATC class groupings do not map cleanly to patent landscapes because:

patents are held and enforced at active ingredient + dosage form + use + route levels,
key exclusivities are often granted to specific branded SKUs, not the whole molecule,
reformulation and combination strategies create “shadow” exclusivities after primary API expiry.

Which patents protect peripheral vasodilators by mechanism of action, and how do they shape exclusivity?

Featured snippet answer: Protection typically clusters in four layers: API composition, formulation/dosage form, method-of-use, and process/manufacturing.

Typical US patent claim categories in C04 products

Composition of matter (API)
- Broadest claims often expire first.
Method-of-use (indication and dosing regimen)
- Can extend practical exclusivity if the brand has an FDA-listed method-of-use patent tied to a marketed indication.
Formulation and dissolution/performance claims
- Tablets/capsules with specific coatings, particle-size distributions, release profiles, or bioavailability targets.
Combination product patents
- Fixed-dose combinations (FDCs) can create independent claim sets even when individual actives are off-patent.

EU/UK typical protection

Supplementary Protection Certificates (SPCs) can extend single-agent protection for marketed actives if eligibility is met.
Company strategies often emphasize process patents and formulation patents that survive primary expiration in litigation or licensing.

When does exclusivity end for peripheral vasodilators, and what timing drives generic entry?

Featured snippet answer: Generic entry is governed by the earliest of API patent expiry, market exclusivity end dates, and “fence” patents listed in the Orange Book for the specific drug product and indication.

Exclusivity timeline mechanics

Key triggers in US practice:

Hatch-Waxman Orange Book patents: composition, method-of-use, and formulation patents tied to the NDA/ANDA.
Regulatory exclusivities (when applicable): can delay ANDA approval even if patents are challenged.
Patent-by-patent litigation and settlement: a brand may settle with an ANDA filer for calendar-based launch slots.

EU/UK exclusivity mechanics

Patent expiry plus SPC expiry often sets the calendar baseline.
Even after SPC expiry, formulation or method-of-use patents can still restrict generic competition depending on infringement scope.

Market dynamic consequence

Manufacturers plan generics around “clean” entry opportunities where claim charts can be avoided:
- No infringement for a key method-of-use claim
- A non-infringing formulation for a dissolution or release claim
- Or a non-infringing combination composition if the brand uses an FDC.

How many patents cover major peripheral vasodilators, and which ones are usually the fence patents?

Featured snippet answer: The highest leverage “fence patents” are typically formulation and method-of-use patents listed in regulatory dossiers for specific strengths/dosage forms.

Patent estate pattern used in competitive planning

For C04 products, licensing and litigation risk usually concentrates in:

one or two “core” granted patents that dominate infringement analyses, and
one or two secondary patents that survive on technicality (bioavailability claims, release profiles, stability, or manufacturing steps).

Practical estate mapping workflow (business lens)

A competitive IP assessment typically prioritizes:

Active ingredient patent status (primary composition)
Orange Book listing count and type (US) for each strength
Method-of-use claims tied to labeled indication(s)
Formulation claims tied to specific dosage forms
Combination patents for branded FDC products
Manufacturing process patents that can block “equivalent” generic supply

What generic entry risks exist for peripheral vasodilators with Orange Book-listed formulation or method-of-use patents?

Featured snippet answer: The highest generic entry risk is when an ANDA must navigate a formulation performance claim or a method-of-use claim that aligns with the labeled indication.

Paragraph IV challenge dynamics

Paragraph IV filings are most strategically attractive when:
- Orange Book listings are limited or easy to design around,
- the brand’s remaining patents are weak on validity or narrow on infringement scope.
Risk increases when:
- multiple patents cover the same SKU,
- formulation patents define release curves or specific excipient systems,
- method-of-use patents match the label in a way that is hard to change.

Design-around routes that commonly succeed

Non-infringing release profile through alternative matrix or coating technology (if allowed under bioequivalence constraints).
Alternative dosage strengths or dosing instructions, if the brand’s method-of-use claims are tightly tailored.
For FDCs, changing component ratios or excipient architecture when not covered by rigid combination claims.

What patent litigation affects peripheral vasodilators, and how do settlements change launch dates?

Featured snippet answer: Litigation outcomes usually translate into fixed launch timing for ANDA filers, with settlement terms driving the market share path more than court merits.

Common settlement structures

Early entry agreements contingent on:
- “design-around” constraints,
- limited market channels,
- or delayed launch of specific strengths.
No-entry or delayed entry if a brand obtains a favorable injunction risk posture or settlement leverage.

Business implication

Even when an ANDA filer wins or avoids a key infringement finding, practical entry can lag due to:
- follow-on patent enforcement,
- appeal timelines,
- supply chain readiness and regulatory acceptance.

What is the Orange Book status of peripheral vasodilators, and how does that map to FDA ANDA approval risk?

Featured snippet answer: Orange Book listings for each branded SKU define where ANDA filers take on Paragraph IV risk; absent listings, the risk shifts primarily to unlisted patents and labeling carve-outs.

Orange Book mapping approach for C04

Identify branded products by active ingredient, strength, and dosage form.
For each NDA:
- enumerate Orange Book patents by claim type,
- isolate method-of-use vs formulation,
- check expiration dates for each patent family member.
For ANDA planning:
- determine which patents must be challenged to reach approval for a given indication/strength.

Regulatory pathway interaction

If a product is eligible for 505(b)(2) or has complex labeling, the IP risk profile can differ materially from a standard ANDA.
For combination products, the regulatory product definition locks the IP analysis around the specific combination.

How does the patent estate for peripheral vasodilators compare across major companies?

Featured snippet answer: Compared to smaller entrants, branded incumbents generally maintain denser estates via reformulations, combination strategies, and method-of-use expansions.

Typical company strategies

Incumbent originators
- Extend via formulation and dosing regimen patents.
- Use lifecycle management to keep Orange Book listings current.
Specialty generics
- Target weakly protected formulations or narrow method-of-use claims.
- File Paragraph IV to force settlement leverage based on litigation cost and uncertainty.

Competitive landscape effect

Companies with robust enforcement histories tend to produce:
- fewer unsolved launch opportunities,
- more settlements that standardize generic launch timing.

What formulations are protected by peripheral vasodilator patents, and what are common claim targets?

Featured snippet answer: Formulation patents often protect release kinetics, excipient systems, and stability properties that support sustained vasodilatory exposure and consistent bioavailability.

Formulation claim targets to look for

Extended-release (ER) matrix or coating systems
Immediate-release (IR) disintegration control
Particle size distribution and milling process
Bioavailability enhancement via solubilizers or salt forms
Stability and shelf-life controlled by packaging and formulation specs

Why this matters for generic products

Bioequivalence alone may not be enough if patents claim performance in a way that correlates to the generic’s release behavior.
Even if a generic meets dissolution specs, an infringement analysis can still turn on claim interpretation and the evidence record.

Method-of-use patents for peripheral vasodilators: which dosing regimens and indications drive infringement risk?

Featured snippet answer: Method-of-use risk concentrates where the brand’s labeled regimen directly matches claim steps, including patient selection criteria and dosing schedule.

Common method-of-use claim elements

Dosing frequency and titration approach
Patient population definitions (if used in claims)
Combination with other therapies or timing relative to other drugs
Monitoring steps tied to therapeutic outcomes

Generic labeling effect

If a generic filer can carve out a method-of-use claim’s steps through labeling limitations, infringement risk can decrease.
If the method-of-use claim corresponds tightly to labeled instructions, generic labeling carve-outs become less practical.

Biosimilar risk in C04: does it apply to peripheral vasodilators?

Featured snippet answer: Biosimilar risk typically applies to biologics, while ATC C04 is predominantly small-molecule peripheral vasodilators; biosimilar-specific patent thickets are usually not the core driver.

Where biologic-like risk can appear

If any C04-branded product is biologic (rare in this class), the IP framework shifts to:
- reference biologic exclusivity,
- biosimilar exclusivity blocks,
- and comparability data package constraints.

Manufacturing and IP barriers for peripheral vasodilators: which process patents can block supply?

Featured snippet answer: Process and impurity-control patents can block generic manufacturing even when the API is otherwise available, especially when patents are tied to specific steps or purity ranges.

Process patent archetypes

Specific synthesis intermediates and reaction conditions
Purification steps achieving defined impurity profiles
Scale-up manufacturing steps that affect critical quality attributes

Enforcement effect

Even if formulation is design-around friendly, a generic may still face injunction risk if process claims are asserted successfully.

Key takeaways

C04 patent risk is best managed at the product-SKU level, not at ATC class level.
The main “fence” patents are usually formulation and method-of-use patents listed in Orange Book for each branded dosage form and strength.
Generic entry timing is driven by the earliest expiry combination across API patents, formulation/method-of-use patents, and any applicable exclusivity periods.
Litigation and settlements translate into launch windows; calendar timing matters as much as validity arguments.

FAQs

How do I assess whether a peripheral vasodilator generic can design around a formulation patent without changing bioavailability?
Which Orange Book patent types (composition vs method-of-use vs formulation) most often determine Paragraph IV settlement outcomes for C04 products?
When does an SPC extend exclusivity for peripheral vasodilators in the EU, and how does it interact with patent expiry?
What labeling carve-outs are feasible to reduce method-of-use infringement risk for peripheral vasodilator generics?
Which manufacturing process patents most commonly block generic launches for small-molecule peripheral vasodilators, and how are they proven in litigation?

References

US Food and Drug Administration. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. FDA.
European Medicines Agency. Supplementary Protection Certificates (SPC) guidance and related regulatory framework. EMA.

Subclasses in ATC: C04 - PERIPHERAL VASODILATORS